1. Chronic GVHD Symptoms Sandra A. Mitchell, CRNP, M.Sc.N., AOCN
National Institutes of Health
Bethesda, MD

2. Self-Report Measures in Chronic Illness Outcome Evaluation
Self-report measures are increasingly a component of outcome evaluation.
Decisions about approving new therapies often incorporate data about the effects of a therapy on symptoms, function or quality of life as primary or secondary outcome measures.
Improved understanding of the impact of chronic GVHD and its symptoms on self-reported health, functional status and quality of life, will contribute to better supportive care.

3. Lee Chronic GVHD Symptom Scale
Instrument developed and psychometrically evaluated by Stephanie J. Lee, M.D., M.P.H. and colleagues1.
Assesses the degree to which respondents are bothered by each of 30 common chronic GVHD symptoms:
Skin
Eyes and Mouth
Breathing
Eating and Digestion
Arthralgias/Myalgias/Limitations in ROM
Fatigue and Asthenia
Emotional Distress
1. Lee, S., Cook, E., Soiffer, R., & Antin, J. (2002). Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 8(8),

4. Lee Chronic GVHD Symptom Scale
Responses are captured on a five-point Likert scale:
“no symptoms or not bothered at all”
“slightly bothered”
“moderately bothered”
“quite a bit bothered”
“extremely bothered”
Time frame of response based on: LAST FOUR WEEKS.
Scores normalized on a 0–100 point scale, and summary and subscale scores can be created.
Higher scores indicate more bothersome symptoms.
Takes about five minutes to complete.

5. Lee Chronic GVHD Symptom Scale: Modifications for Pediatrics
Validity evidence supports Lee Chronic GVHD Symptom Scale as a self-report measure for adults.1
Adolescents 13 years and older: independent self-report.
Children 8-12 years: measure completed with assistance from health care provider.
1. Lee, S., Cook, E., Soiffer, R., & Antin, J. (2002). Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 8(8),